An FDA advisory panel voted 7-2 (with one abstention) that Galleri’s benefits outweigh its risks, and the split on effectiveness, 6-4 in favor, tells you almost everything about where this test stands heading into the agency’s final decision. GRAIL’s multi-cancer early detection test cleared the Molecular and Clinical Genetics Devices Panel on September 23, with all ten members voting unanimously on safety. The 6-4 effectiveness split, though technically favorable, signals that the panel’s confidence is real but not overwhelming, and the FDA is not bound by any of those votes.
The clinical foundation behind those votes is substantial. The PATHFINDER 2 trial enrolled 35,878 adults aged 50 and older across North America and found that adding Galleri to standard screening increased cancer detection 6.5-fold. The NHS-Galleri randomized trial in England, which ran across more than 140,000 participants, did not meet its primary endpoint of reducing combined late-stage cancers overall, but it did show a reduction in stage IV diagnoses specifically. GRAIL’s own summary, citing pooled clinical data, puts Galleri’s detection advantage at roughly four to seven times more cancers versus standard of care alone, with most found at earlier stages. That range matters: a panel member voting “no” on effectiveness can look at the NHS-Galleri primary miss and reach a defensible conclusion.
The test works by identifying cancer-specific methylation patterns in blood before symptoms appear, including cancer types without recommended screening, and it predicts cancer signal origin with enough accuracy to guide the next diagnostic step rather than send patients into undirected workups. GRAIL positions Galleri as an addition to, not a replacement for, existing recommended screenings. The FDA granted Breakthrough Device designation back in 2018, and GRAIL submitted its premarket approval application in January 2026. That PMA represents the first submission of its kind for an MCED test.
The FDA now completes its own review, with a decision expected within months. The number to watch is not the advisory vote tally but the final agency ruling on effectiveness, because a conditional or restricted approval tied to post-market study requirements would meaningfully shape how broadly the test reaches patients and whether payers treat the panel’s 6-4 split as a reason to hold coverage decisions until long-term outcome data matures.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
